KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Diluted Average) (2019 - 2025)

Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $134.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 5.51% year-over-year to $134.7 million; the TTM value through Dec 2025 reached $134.7 million, up 5.51%, while the annual FY2025 figure was $134.7 million, 5.51% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $134.7 million in Q4 2025 per ALNY's latest filing, roughly flat from $134.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $134.7 million in Q4 2025 to a low of $117.1 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $124.6 million, with a median of $124.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 1.42% in 2024, then increased 5.51% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $118.5 million in 2021, then rose by 2.73% to $121.7 million in 2022, then rose by 2.64% to $124.9 million in 2023, then grew by 2.2% to $127.7 million in 2024, then increased by 5.51% to $134.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Shares Outstanding (Diluted Average) are $134.7 million (Q4 2025), $134.1 million (Q3 2025), and $130.2 million (Q2 2025).